180 Life Sciences Corp.
ATNF
$3.00
$0.8740.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.41M | 2.00M | 997.60K | 576.40K | 1.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.73M | 2.37M | 1.41M | 979.10K | 1.85M |
| Operating Income | -1.73M | -2.37M | -1.41M | -979.10K | -1.85M |
| Income Before Tax | -1.73M | -2.37M | -4.57M | -836.70K | 11.80K |
| Income Tax Expenses | -- | -- | -296.00K | -- | -- |
| Earnings from Continuing Operations | -1.73M | -2.37M | -4.27M | -836.70K | 11.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.73M | -2.37M | -4.27M | -836.70K | 11.80K |
| EBIT | -1.73M | -2.37M | -1.41M | -979.10K | -1.85M |
| EBITDA | -1.72M | -2.36M | -1.39M | -965.20K | -1.82M |
| EPS Basic | -0.30 | -0.67 | -10.95 | -0.85 | 0.01 |
| Normalized Basic EPS | -0.19 | -0.42 | -1.69 | -0.56 | -0.10 |
| EPS Diluted | -0.30 | -0.67 | -10.95 | -0.85 | 0.01 |
| Normalized Diluted EPS | -0.19 | -0.42 | -1.69 | -0.56 | -0.10 |
| Average Basic Shares Outstanding | 5.71M | 3.54M | 1.12M | 980.60K | 919.10K |
| Average Diluted Shares Outstanding | 5.71M | 3.54M | 1.12M | 980.60K | 919.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |